Aimmune Therapeutics News Releases http://ir.aimmune.com/ Aimmune Therapeutics News Releases en Aimmune to Present at the JMP Securities Life Sciences Conference http://ir.aimmune.com/news-releases/news-release-details/aimmune-present-jmp-securities-life-sciences-conference BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 12, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas , M.D., will present at the JMP Wed, 12 Jun 2019 08:00:00 -0400 Aimmune Therapeutics News Releases 9066 Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting http://ir.aimmune.com/news-releases/news-release-details/aimmune-therapeutics-discusses-ar101s-cost-effectiveness-and Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 11, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the Tue, 11 Jun 2019 08:00:00 -0400 Aimmune Therapeutics News Releases 9056 Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference http://ir.aimmune.com/news-releases/news-release-details/aimmune-participate-goldman-sachs-40th-annual-healthcare BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 5, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Wed, 05 Jun 2019 08:00:00 -0400 Aimmune Therapeutics News Releases 9051 Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy http://ir.aimmune.com/news-releases/news-release-details/data-two-studies-confirm-quality-life-and-psychosocial-burden --APPEAL 2: Struggle to Avoid Accidental Peanut Exposure Negatively Impacts Quality of Life for Patients and Families-- --Phase 3 PALISADE Follow-on Study Analysis: Improvements in Quality of Life for Peanut-Allergic Patients after Continued AR101 Treatment-- LISBON, Portugal --(BUSINESS Tue, 04 Jun 2019 10:01:00 -0400 Aimmune Therapeutics News Releases 9041 New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year http://ir.aimmune.com/news-releases/news-release-details/new-data-phase-3-palisade-follow-study-ar101-peanut-allergy-show --Patients tolerated as much as 2,000 mg of peanut protein with fewer adverse events -- --Favorable ongoing and notable immunological changes observed over time-- LISBON, Portugal --(BUSINESS WIRE)--Jun. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing Tue, 04 Jun 2019 07:01:00 -0400 Aimmune Therapeutics News Releases 9036 Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy http://ir.aimmune.com/news-releases/news-release-details/pivotal-phase-3-artemis-trial-data-demonstrates-consistent LISBON, Portugal --(BUSINESS WIRE)--Jun. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously Sun, 02 Jun 2019 07:01:00 -0400 Aimmune Therapeutics News Releases 9031 Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress http://ir.aimmune.com/news-releases/news-release-details/aimmune-present-ar101-data-european-academy-allergy-and-clinical – Full Results from Phase 3 ARTEMIS Study Will Be Featured – BRISBANE, Calif. --(BUSINESS WIRE)--May 24, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient Fri, 24 May 2019 08:00:00 -0400 Aimmune Therapeutics News Releases 8986 New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut http://ir.aimmune.com/news-releases/news-release-details/new-study-shows-more-half-teens-peanut-allergy-visited-er-more -- 4 in 10 Teens believe they have a great or very great chance or certainty of dying from accidental exposure -- NEW ORLEANS --(BUSINESS WIRE)--May 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today Tue, 21 May 2019 16:01:00 -0400 Aimmune Therapeutics News Releases 8981 Aimmune to Present at RBC Capital Markets Global Healthcare Conference http://ir.aimmune.com/news-releases/news-release-details/aimmune-present-rbc-capital-markets-global-healthcare-conference BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt , will present at the RBC Capital Markets Global Thu, 16 May 2019 08:30:00 -0400 Aimmune Therapeutics News Releases 8971 Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy http://ir.aimmune.com/news-releases/news-release-details/aimmune-announces-us-fda-advisory-committee-meeting-date-ar101 - Company Enters into Commercial Supply Agreement for AR101 - BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S. Thu, 16 May 2019 08:00:00 -0400 Aimmune Therapeutics News Releases 8966